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Abstract The multicatalytic protease (MCP) or 20S pro- 
teasome was purified from human red blood cells and two lym- 
phoblastoid cell lines, 721.45 which constitutively expresses pro- 
tease subunits LMP2 and LMP7, and 721.174 in which genes for 
these subunits are deleted. Each MCP was assayed using a series 
of fluorogenic peptides. The hydrophobic peptides gGGF-MCA, 
sRPFHLLVY-MCA and sLY-MCA were particularly good sub- 
strates for 721.45 MCP as compared to the enzyme from 721.174 
and red blood cells. In addition, hydrolysis of gGGF-MCA and 
sLY-MCA was activated by human red blood cell and recombi- 
nant regulators to a greater extent using MCP from 721.45 
lymphoblasts. Thus, LMP2/LMP7 and regulator appear to act 
synergistically in the enhanced degradation of gGGF-MCA and 
sLY-MCA by the multicatalytic protease. 
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1. Introduction 
The multicatalytic protease (MCP) or 20S proteasome is a 
large multisubunit enzyme abundant in the nucleus and cyto- 
plasm of eukaryotic ells [1-3]. MCP has a native molecular 
weight of ~ 700 kDa, and in eukaryotes it is composed of at least 
14 distinct subunits with molecular masses between 21 and 32 
kDa [4]. The subunits are arranged in four rings each contain- 
ing 7 subunits; the rings stack upon one another to form a 
cylindrical structure [5]. The multicatalytic protease xhibits at 
least five endopeptidase activities that cleave bonds at the car- 
boxyl side of basic, hydrophobic-neutral and acidic amino acids 
[6]. It has long been suspected that the active sites are buried 
within the cylinder [3], and the recently reported X-ray struc- 
ture of the Thermoplasma proteasome confirms this suspicion 
[7]. 
MCP is believed to be responsible for the degradation of 
many nuclear and cytosolic proteins. It has been demonstrated 
that the mutticatalytic enzyme associates with two additional 
multisubunit complexes. One is an 11S regulator which in red 
blood cells is composed of two distinct -30 kDa subunits [8-11 ]. 
Binding of the 11S regulator with MCP can enhance MCP's 
peptidase activity as much as 60-fold. The other is a regulatory 
complex composed of at least 15 different subunits [12-16]. 
Association of MCP with the regulatory complex produces the 
26S protease which is responsible for ATP-dependent degrada- 
tion of ubiquitin-conjugated proteins. As part of the larger 26S 
enzyme, MCP is clearly involved in key cellular functions uch 
as cell cycle traverse and selective intracellular proteolysis (for 
reviews, see [17-19]). 
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Two MCP subunits, LMP2 and LMP7, are encoded in the 
MHC-class II genomic region [20,21], and their expression is 
upregulated by IFN 7 [22]. These findings suggest hat MCP 
may be involved in the processing of cellular proteins for MHC- 
class I antigen presentation. Supporting the potential role of 
MCP in class I-mediated immune responses is the fact that 
synthesis of an 11S regulator subunit is also stimulated by 
IFNy [23]. Conceivably, the subunit composition of MCP and 
its response to the regulator influence the production of pep- 
tides for presentation on MHC-class I molecules [24,25]. Here, 
we show that MCP from human lymphoblasts expressing 
LMP2 and LMP7 hydrolyzes several fluorogenic peptides 
faster than MCP from a derivative cell line lacking the MHC 
II-encoded subunits. Moreover, both red blood cell and recom- 
binant regulators enhance cleavage of these peptides by MCP 
containing LMP2 and LMP7 to a greater extent than they 
stimulate the enzyme from mutant lymphoblasts. 
2. Materials and methods 
MCP and 11S regulator were prepared from 20 units of outdated 
human red blood cells following the protocols of Dubiel et al. [10,26]. 
MCPs from human lymphoblastoid cell lines 721.45 and 721.174 were 
purified as described [27] except hat a 55-80% ammonium sulfate 
precipitation step was introduced between DEAE chromatography and 
glycerol gradient centrifugation. Recombinant regulator was purified 
from Escherichia coli after induction with IPTG. Briefly, the cells were 
lysed using a french press and the lysate passed over an anion exchange 
column followed by sizing chromatography. 
MCP peptidase activity was assayed as follows: 200-ng aliquots of 
each purified MCP were incubated at 37°C with 100/IM fluorogenic 
peptide in 100/ll of 50 mM Tris, 25 mM KC1, 10 mM NaCI, 1.1 mM 
MgC12, 0.1 mM Na EDTA, 1 mM DTT, pH 7.8. Duplicate samples 
were quenched after 20 and 40 min by adding 200,ul of ice-cold ethanol. 
Fluorescence was determined ina Perkin-Elmer LS-5 fluorimeter at 380 
nm excitation/440 nm emission wavelengths for MCA and 335 nm 
excitation//410 nm emission wavelengths for fl-NA peptides. Human 
RBC regulator (2.6 ,ug) was added to the reaction mixtures containing 
MCPs; alternatively, 3.6/lg of recombinant regulator was added. Sam- 
ples were preincubated in the presence of regulator for 10 min at 37°C 
before adding substrate. Specific activities are expressed as pmol/min/ 
/.tg of MCP. 
3. Results 
MCPs were isolated from human red blood cells and the two 
human lymphoblastoid lines, 721.45 and 721.174. In addition, 
human 11S regulator was partially purified from red blood cells 
and the recombinant regulator, containing just the 29 kDa 
subunit, was purified from E. coll. The purity of each compo- 
nent was assessed by electrophoresis on 10% SDS-PAGE gels 
(Fig. 1). The purified multicatalytic proteases were incubated 
with 21 different fluorogenic peptides. Cleavage was < 1 pmol/ 
min//lg for fluorogenic peptides with a proline in position P1 
All rights reserved. 
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Fig. 1. SDS-PAGE analysis of MCPs and regulators. Proteins were 
purified as described under experimental procedures and separated on 
a 10% polyacrylamide g l followed by silver staining. 
or P2 as well as for boc-EKK-MCA, cbz-RRR-MCA, boc- 
IEGR-MCA and suc-AAA-MCA. Specific activities for the 
remaining fluorogenic peptides are listed in Table 1. In general, 
the multicatalytic protease from human RBCs cleaved fluoro- 
genie peptides at a lower rate than the enzyme from lympho- 
blasts, and except for cLLE-flNA, most fluorogenic peptides 
were hydrolyzed faster by 721.45 MCP than by 721.174 MCE 
The most striking differences between 721.45 and 721.174 
MCPs were observed with three hydrophobic peptides, 
sRPFHLLVY-MCA, gGGF-MCA and sLY-MCA. The multi- 
catalytic protease containing LMP2 and LMP7 (721.45 cells) 
hydrolyzed these peptides 3-7-fold faster than MCP from 
721.174 cells. 
Fluorogenic peptides with identical amino acids at the P1 
position varied markedly as substrates ( ee Table 1). For exam- 
ple, rates of hydrolysis for two peptides with tyrosine at the PI 
position differed by 20-fold using the red blood cell enzyme. In 
addition, hydrolysis of four peptides with arginine at the P1 
position varied as much as 5-fold using each of the enzymes. 
Thus, in agreement with a number of other studies [6,28,29], we 
found that the amino acid residue at the P1 position does not 
uniquely determine rates of peptide hydrolysis by MCE 
We also assayed each MCP in the presence of red blood cell 
or recombinant regulators. Equivalent saturation curves were 
obtained upon incubation of MCP from each cell type with 
increasing amounts of red blood cell regulator (Fig. 2). The 
recombinant regulator produced similar results except that 
greater amounts of protein (3.6 pg) were required to reach 
saturation (data not shown). MCP activity was reassayed 
against he panel of fluorogenic substrates in the presence of 
saturating amounts of red blood cell or recombinant regulator. 
It is evident from the data in Table 2 that hydrolysis of most 
peptides was activated to about the same extent with each 
enzyme. However, cleavage of gGGF-MCA and sLY-MCA 
was stimulated more using 721.45 MCP and hydrolysis of two 
substrates with basic residues at the P1 position, FSR-MCA 
and bVLK-MCA, was stimulated almost 2-fold greater using 
MCP from 721.174 cells. The results in Table 2 also demon- 
strate that recombinant and red blood cell regulators stimulate 
cleavage of specific peptides in a very similar manner. Red 
blood cell or recombinant regulators did not promote hydroly- 
sis of any peptide that was not already a substrate (data not 
shown). 
4. Discussion 
We previously reported that MCP from 721.45 cells hydro- 
lyzes gGGF-MCA more efficiently than MCP from 721.174 
cells [27]. The experiments presented above extend these find- 
ings to sLY-MCA and sRPFHLLVY-MCA as well (Table 1). 
Except for the absence of LMP2 and LMP7 subunits in mutant 
cell lines, two-dimensional gel patterns of MCP components are 
very similar among mutant and parental lymphoblast lines (e.g. 
T1 vs. T2 [30]). For this reason, we consider it reasonable to 
attribute the observed ifferences in enzymatic activity between 
721.45 and 721.174 MCPs to the LMP2 and/or LMP7 subunits. 
If this assumption is correct, then the ratio of sLLVY-MCA to 
sLY-MCA cleavage could prove to be a useful measure of the 
presence of LMP2 and/or LMP7 subunits in proteasomes. It 
is apparent from the data in Table 1 that this ratio is 3 for MCP 
from 721.45 cells, 12 for MCP from 721.174 cells, and 19 for 
MCP from red blood cells. A ratio <5 could imply the presence 
of LMP2 and LMP7, whereas a ratio >10 may indicate the 
absence of the two subunits. In any event, the data in Table 1 
demonstrate hat there are clear differences in the patterns of 
peptide hydrolysis by MCPs from 721.45 and 721.174 lympho- 
blasts. 
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Fig. 2. Activation of sLLVY-MCA cleavage by red blood cell regulator. 
The graph shows regulator-dependent activation of peptide hydrolysis 
by MCPs from 721.45 cells (©), 721.174 cells (e) and RBCs (A). 
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Table 1 
Substrate specificities of lymphoblast and red blood cell multicatalytic 
proteases 
Substrate Specific activities (pmol/min/ctg) 
RBC-MCP 721.45 MCP 721.174 MCP 
Basic 
Boc-FSR-MCA 5 + 2 16 + 4 8 _+ 2 
(n = 8) (n = 6) (n = 4) 
PFR-MCA 3 + 1 9_+ 3 10_+ 4 
(n = 7) (n = 9) (n = 6) 
Boc-VLK-MCA 1 + 0.2* 5 + 1 3 + 1 
(n = 8) (n = 6) (n = 6) 
Boc-EGR-MCA 4 -+ 2 3 + 1 2 + 0.3 
(n = 8) (n = 8) (n = 4) 
Boc-GKR-MCA 1 + 0.6* 3 -+ 1 2 + 1 
(n = 8) (n = 4) (n = 6) 
Acidic 
N-Cbz-LLE-flNA 29 + 10 33 + 5 61 + 11 
(n = 8) (n = 5) (n = 6) 
Hydrophobic 
Suc-LLVY-MCA 58 + 10 145 + 18 92 + 24 
(n = 6) (n = 4) (n = 4) 
Suc-RPFHLLVY-MCA 5 18 6 
Suc-AAF-MCA 6 + 3 40 + 13 21 + 2 
(n = 8) (n = 8) (n = 4) 
GIu-GGF-MCA 4 -+ 1 30 + 6 11 + 1 
(n = 8) (n = 6) (n = 6) 
Suc-LY-MCA 3 + 1 51 + 5 8 + 1 
(n = 8) (n = 4) (n = 4) 
*Values <1 pmol/min//lg are below the limit of detection. Peptides are 
identified using the one-letter amino acid code. 
Both regulator and the LMP subunits promote rapid hydrol- 
ysis of gGGF-MCA and sLY-MCA (Table 2). Because regula- 
tor and LMP subunits are induced by IFNF  [22,23], the ob- 
served synergism supports the idea that IFN F induction serves 
to alter the kinetic properties of MCP. One can speculate that 
I FN?  induction of the three components hifts cleavage sites 
in natural precursors uch that the resulting peptides are less 
'self-like' or have C-termini appropriate for binding MHC-class 
I molecules. This inference may seem at odds with a previous 
paper from this laboratory where we called into question claims 
that IFN F alters the kinetic properties of purified proteasomes 
[31]. We consider both conclusions compatible. In our earlier 
studies (27) exposure of 721.45 or 721.174 human lymphoblasts 
to IFN7 did not markedly alter the enzymatic activities of 
purified proteasomes from either line. Still, there are major 
differences in hydrolysis of fluorogenic peptides between the 
two cell lines, and these differences are magnified by the 11S 
regulator. Since IFNy  induces synthesis of the regulator sub- 
unit [23], the cytokine may well indirectly influence selection of 
cleavage sites by the multicatalytic protease. 
All the data presented above were obtained using fluorogenic 
peptides. It can be argued that MCA-peptides are artificial 
substrates and therefore have no bearing on the intracellular 
production of peptides for immune presentation. The same 
arguments can be used to evaluate other studies where longer, 
non-fluorogenic peptides have been employed [32-34]. The na- 
ture of endogenous precursors to presented peptides remains 
unclear (e.g. folded proteins or nascent chains?, long peptides 
or short ones?, ubiquitin peptides?, etc.). Furthermore, the 
small central cavity formed by the two fl rings [7] would seem 
to require that substrates are unfolded at the time of peptide 
bond hydrolysis. Accordingly, we believe it is reasonable to 
infer that the differences in MCP activities revealed by fluoro- 
genic peptides reflect inherent properties of the enzyme that 
determine cleavage site selection in natural substrates. 
In summary, we have shown that multicatalytic proteases 
from human red blood cells and human lymphoblasts hydro- 
lyze specific fluorogenic peptides at significantly different rates. 
MCP containing LMP2 and LMP7 subunits (721.45 cells) is 
particularly efficient at hydrolyzing several peptides with hy- 
drophobic residues at the P1 position. Moreover, the regulator 
stimulates cleavage of these same hydrophobic peptides to a 
greater extent by MCP containing the MHC II-encoded sub- 
units. Since IFN F induces the synthesis of LMP2, LMP7 and 
the 29 kDa regulator subunit, it seems likely that the cytokine 
alters the substrate specificity of MCP in vivo. In addition, the 
observed changes in specificity are consistent with the idea that 
MCP is responsible for generating peptides presented on class 
I molecules. 
Table 2 
Stimulation of MCP peptidase activities by RBC vs. recombinant regulator 
Stimulation (x-fold) 
RBC-MCP 721.45 MCP 721.174 MCP 
Red cell Recomb. Red cell Recomb. Red cell Recomb. 
regulator regulator regulator regulator regulator regulator 
Basic 
FSR-MCA 16 8 12 I 1 21 21 
PFR-MCA 9 7 l0 9 6 I 1 
VLK-MCA 20 14 12 8 16 22 
GKR-MCA 8 6 6 5 7 1 l 
Acidic 
LLE-2NA 12 11 14 10 7 12 
Hydrophobic 
LLVY-MCA 27 20 27 23 19 39 
AAF-MCA 20 12 20 12 18 19 
GGF-MCA 2 2 6 5 2 2 
LY-MCA 11 8 16 15 10 l 1 
Each entry presented above is an average from 2 to 6 independent experiments. 
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